| CASE REPORT |
|
| Year : 2020 | Volume
: 35
| Issue : 3 | Page : 226-228 |
|
|
Whole-body and single-photon emission computed tomography/computed tomography postpeptide receptor alpha radionuclide therapy images of actinium 225-tetraazacyclododecanetetraacetic Acid–Octreotide as a primary modality of treatment in a patient with advanced rectal neuroendocrine tumor with metastases
Koramadai Karuppusamy Kamaleshwaran1, Malipedda Suneelkumar1, Raghunathan Madhusairam2, Edathuruthy Kalarikal Radhakrishnan1, Soundararajan Arunpandiyan1, Vasumathi Jayaraj Arnold1
1 Department of Nuclear Medicine, PET/CT and Radionuclide Therapy, Comprehensive Cancer Care Center, Kovai Medical Center and Hospital Limited, Coimbatore, Tamil Nadu, India
2 Department of Radiation Oncology, Comprehensive Cancer Care Center, Kovai Medical Center and Hospital Limited, Coimbatore, Tamil Nadu, India
Correspondence Address:
Dr. Koramadai Karuppusamy Kamaleshwaran
Department of Nuclear Medicine, PET/CT and Radionuclide therapy, Comprehensive Cancer Care Center, Kovai Medical Center and Hospital Limited, Coimbatore - 641 014, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijnm.IJNM_58_20
|
|
|
Somatostatin receptor-targeted alpha radionuclide therapies have been introduced including actinium-225 labeled tetraazacyclododecanetetraacetic acid–octreotide (Ac-225 DOTATATE) for advanced metastatic neuroendocrine tumors (NET). Very limited data are available on the posttherapy imaging using Ac-225 DOTATATE therapy in metastatic NET. We present Ac-225 single-photon emission computed tomography/computed tomography images of a 72-year-old patient diagnosed as a case of advanced rectal NET treated primarily with Ac-225 DOTATATE.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
